What the safety record actually shows

The short answer is yes — ChondroFiller injection has a strong safety record, and the numbers behind that record are unusually concrete.

Post-market surveillance compiled by manufacturer Meidrix Biomedicals GmbH — covering more than 19,000 treated cases since ChondroFiller entered clinical use in 2013 — has recorded zero serious adverse device effects (SADEs). A serious adverse device effect is any unintended consequence of the device itself that causes significant harm: organ damage, hospitalisation, or lasting injury. Across more than a decade of real-world use, none have been reported. The overall complaint rate sits at approximately 0.06%, and the most commonly logged device issue — non-gelation, where the collagen scaffold does not set correctly inside the defect — occurs in roughly 0.01% of cases. Non-gelation is a procedural outcome rather than a patient-harm event.

That manufacturer-sourced picture is independently supported by a 2025 prospective study by Matta et al., published on PubMed Central, which found no significant difference in complications between ChondroFiller-treated patients and controls in wrist cartilage repair.

One qualification runs through all of these figures: they reflect outcomes in carefully screened, appropriately selected patients — which is precisely why patient selection is covered in full in the sections that follow.

Side effects to expect in the first 48–72 hours

Three symptoms are expected in the 48–72 hours after a ChondroFiller injection: localised joint swelling, a temporary pain flare, and stiffness around the treated area. These are predictable physiological responses to placing a collagen gel inside a joint — the tissue reacts to a new material in the space, and a short-lived inflammatory-style process is part of that normal response. It is not a sign that something has gone wrong, and it does not indicate treatment failure.

All three typically resolve without any intervention within a few days. Mild analgesics and rest can help manage discomfort during this window, though most patients find the response manageable.

It is worth being clear about what these symptoms are not. Swelling, a pain flare, and stiffness in the first few days are part of the expected post-procedure course. They are separate from the rare adverse events — joint infection, allergic reaction, and fibrous tissue formation — which are covered in the section that follows. Conflating the two is a source of unnecessary anxiety; the physiological response is self-limiting, the rare risks are a different category entirely.

Who should not have the ChondroFiller injection

Allergy screening comes first — and for this treatment, it is not a routine box-tick. Because ChondroFiller is purified from the tail tendons of specific pathogen-free laboratory rats, every patient must be assessed for sensitivity to murine proteins or collagen before the injection takes place. That biological origin is what makes the scaffold effective; it is also why this screening step is non-negotiable and unique to this product among injectable cartilage therapies.

Beyond allergy status, a number of clinical conditions place a patient outside the treatment indication entirely:

• Confirmed allergy to rat-derived proteins or collagen
• Active infection — whether localised to the target joint or systemic
• Uncontrolled bleeding disorders
• Immunosuppression or active malignancy
• Pregnancy or breastfeeding, where no safety data exist

Diffuse osteoarthritis also falls outside the indication. The scaffold is designed to fill and stabilise a focal defect — it depends on healthy surrounding cartilage to anchor and support it. In a joint with widespread degeneration, such as Kellgren-Lawrence Grade IV disease, that stable cartilage border is absent. ChondroFiller is indicated for focal defects up to 6 cm²; patients whose damage extends beyond that profile are not suitable candidates.

These criteria are not arbitrary clinical bureaucracy. They are, in large part, the reason the serious adverse device effect rate across more than 19,000 cases has remained at zero. Keeping that record intact requires that the treatment reaches only the patients for whom it was designed — which is why a specialist assessment is the starting point for any suitability decision.

Rare but recognised risks

Four risk categories sit outside the expected post-procedure course — uncommon in properly selected and treated patients, but worth understanding clearly.

Joint infection is a theoretical risk with any intra-articular injection. In practice, ultrasound guidance and strict sterile technique reduce this to an extreme rarity; it is not a risk specific to ChondroFiller.

Allergic or immunologic reaction to the murine-derived collagen remains rare in patients who have completed mandatory allergy screening. The screening requirement exists precisely because the biological origin creates a small but real sensitisation risk — which is why it cannot be skipped.

Fibrous tissue formation can occur if the defect is overfilled. The scaffold needs to fill the cartilage lesion, not exceed it; when it does, the result may be fibrous rather than hyaline-like repair tissue. This is a technique-sensitive outcome — careful assessment of defect volume and precise delivery directly reduce its likelihood.

Non-gelation — the most common device-specific complaint in post-market data — occurs at approximately 0.01%. This is a product performance event, not a patient-harm event, but it is clinically relevant because it means the scaffold has not set correctly and the treatment may need to be repeated.

None of these are routine expectations. They are the edge cases that careful patient selection, allergy screening, and precise technique are specifically designed to prevent.

The post-injection recovery phase

Planning your schedule around the injection matters. For the first 2–3 weeks after treatment, heavy joint loading and running are off the table — not as a general suggestion, but as a clinical condition of the procedure.

The reason is mechanical. Once injected, the collagen gel begins to set within the defect and recruit the surrounding tissue. That integration process requires a stable environment: if the joint is loaded heavily or subjected to high-impact movement before the scaffold has fixated, there is a real risk of displacing or disrupting it before it has had the chance to mature. The quiet phase is what allows the gel to do its job.

In practical terms, this means most patients need to adjust their daily routine — lighter walking is typically acceptable, but returning immediately to sport, heavy manual work, or prolonged standing is not. Patients who plan ahead and arrange appropriate cover for physically demanding commitments in the days after their injection will find this phase significantly easier to manage.

Evidence quality, regulatory status, and getting assessed in the UK

No blinded randomised controlled trial has been published for ChondroFiller. The safety figures discussed throughout this article originate from manufacturer-sponsored post-market clinical surveillance by Meidrix Biomedicals GmbH, with one independent external anchor in the 2025 Matta et al. prospective study. That is a substantial evidence base, but patients weighing a treatment decision deserve to know its provenance.

CE Class III classification places ChondroFiller in the EU's highest medical-device risk tier. Many patients assume CE marking is a routine quality stamp; it is considerably more. Class III devices — the same tier as cardiac implants — require clinical evidence submission, independent review by an accredited notified body, and mandatory ongoing post-market surveillance commitments. The zero SADE rate and 0.06% complaint record exist in published form because that framework requires systematic collection of precisely this data.

ChondroFiller is not FDA-approved and is imported into the UK under individual prescription, making specialist assessment a prerequisite rather than an administrative step. It is worth restating that the favourable safety figures apply to a carefully selected population — patients with focal cartilage defects, intact surrounding cartilage borders, and no active contraindications. They do not transfer automatically to broader or less-selected groups.

In the UK, ChondroFiller injection is available at the London Cartilage Clinic on Harley Street, where a specialist assessment establishes whether the treatment is appropriate for the specific defect, joint, and clinical picture. That consultation is also where the evidence limitations above become consequential: understanding what the published data does and does not show is what allows a clinician to apply it responsibly to an individual case, rather than to a studied population.